(Total Views: 588)
Posted On: 08/12/2020 7:28:14 PM
Post# of 153822
You are correct CDiddy that the trial size will be small and the primary endpoint for the m2m P3 would be NEWS2 outcome....but um....statistically significant efficacy was already shown with the P2....so....WHY?!??
Now...if they wanted to pursue a trial to retest for primary endpoint (from P2 trial), they would need to increase the population size to get beyond clinically significant to statistically significant. But why? They already have statistically significant result with secondary endpoint (NEWS2).
I found this circular logic illogical. My thinking is that even CYDY's doctors have no idea why the EFF-DA would reject the EUA other than the EFF-DA doing what it's been doing to them...EFFing with them.
Now...if they wanted to pursue a trial to retest for primary endpoint (from P2 trial), they would need to increase the population size to get beyond clinically significant to statistically significant. But why? They already have statistically significant result with secondary endpoint (NEWS2).
I found this circular logic illogical. My thinking is that even CYDY's doctors have no idea why the EFF-DA would reject the EUA other than the EFF-DA doing what it's been doing to them...EFFing with them.
(1)
(1)
